Anti-interleukin-6 (tocilizumab) therapy in Takayasu's arteritis: a real life experience

Creative Commons License

KILIÇ L., KARADAĞ Ö., Erden A., SARI A., ARMAĞAN B., YARDIMCI G. K., ...Daha Fazla

TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.50, sa.1, ss.31-36, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 50 Sayı: 1
  • Basım Tarihi: 2020
  • Doi Numarası: 10.3906/sag-1906-39
  • Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.31-36
  • Anahtar Kelimeler: Anti-interleukin-6, tocilizumab, Takayasu's arteritis, GIANT-CELL ARTERITIS, DISEASE-ACTIVITY, CASE SERIES, EFFICACY, RESISTANT, SAFETY
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background/aim: Tumour necrosis factor inhibitors and anti-interleukin-6 (anti-IL-6) therapies are increasingly being used in Takayasu's arteritis (TA) patients who are unresponsive to corticosteroids +/- conventional immunosuppressive agents. The aim of this study is to assess the efficacy and safety of anti-IL-6 (tocilizumab) therapy in refractory TA patients in real life.